Plain-English translation of NCT07406035 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether TQH3906, a new oral capsule, can help treat active psoriatic arthritis. Researchers will compare the medication at two different doses against a placebo (a dummy pill with no medication) and against an existing treatment called tofacitinib to see which works best. The study will track how much improvement people experience over 12 weeks.
Psoriatic arthritis can cause serious joint damage and significantly impact quality of life, and many patients don't get adequate relief from current treatments. This trial aims to determine if this new medication might offer another effective option for people whose arthritis has been difficult to control.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to take one of four treatments daily by mouth for about 12 weeks: the new medication at a higher dose, the medication at a lower dose, a placebo pill, or an existing arthritis medication. You'll visit the study clinic several times so doctors can check your joint swelling, pain levels, and overall response to treatment. The main goal is to measure how many people improve by at least 20% in their arthritis symptoms by week 12.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China